Strides Pharma Science Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Strides Pharma Inc receives USFDA closure report (EIR) for its formulations facility at Chestnut Ridge, New YorkInspection included Drug Device Combinations covering our recent filling in Nasal Sprays domain".
STAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Strides Pharma Science has informed the exchange about a USFDA Establishment Inspection Report (EIR) for its formulations facility located at Chestnut Ridge, New York. The closure report relates to an inspection that covered Drug Device Combinations, including the company's recent forays into the Nasal Sprays domain. An EIR from the USFDA typically signifies that the inspection of the facility has been formally closed by the regulator. The Chestnut Ridge plant is a key manufacturing site for Strides' US business, and clearance removes regulatory uncertainty around production from this facility.
Positive development for shareholders — USFDA closure report indicates the facility meets regulatory standards, allowing uninterrupted supplies to the US market and supporting future growth in the nasal sprays segment. Likely to be viewed favourably by the market as a regulatory overhang is cleared.